Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01181297
Other study ID # 3369-2
Secondary ID
Status Completed
Phase N/A
First received August 12, 2010
Last updated August 12, 2010
Start date January 2003
Est. completion date November 2004

Study information

Verified date August 2010
Source Mead Johnson Nutrition
Contact n/a
Is FDA regulated No
Health authority The Netherlands: Medisch Ethische Toetsingscommissie
Study type Interventional

Clinical Trial Summary

The purpose of this study is to confirm the hypoallergenicity of an extensively hydrolyzed formula with an added probiotic in children with documented milk allergy.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date November 2004
Est. primary completion date November 2004
Accepts healthy volunteers
Gender Both
Age group N/A to 14 Years
Eligibility Inclusion Criteria:

- =14 years of age

- Essentially asymptomatic for a minimum of 7 days pre-challenge.

- Successful previous consumption of Extensively Hydrolyzed Formula within 1 week of study enrollment

- Medically documented allergy to cow's milk

Exclusion Criteria:

- Presence of underlying systemic disease or other illness

- Used Beta-blockers within 12-24 hours of challenges

- Use of short-acting antihistamines within 3 days

- Use of medium-acting antihistamines within 7 days

- Use of long-acting antihistamines within 6 weeks

- Use of oral steroid medication within 3 weeks

Study Design

N/A


Related Conditions & MeSH terms


Intervention

Other:
Extensively Hydrolyzed Formula with a Probiotic

Extensively Hydrolyzed Formula without a Probiotic


Locations

Country Name City State
Italy Dept. of Paediatrics, Azienda Ospedaliera di Padova Padova Veneto
Netherlands Wilhelmina Children's Hospital Utrecht

Sponsors (1)

Lead Sponsor Collaborator
Mead Johnson Nutrition

Countries where clinical trial is conducted

Italy,  Netherlands, 

See also
  Status Clinical Trial Phase
Terminated NCT02032056 - Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period N/A
Completed NCT01842711 - Cumulative Irritation Patch Test N/A
Completed NCT01633840 - New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges N/A
Completed NCT00554983 - Efficacy and Safety From a Recombinant Folding Variant of Bet v 1 Phase 3
Completed NCT00997971 - Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein Phase 3
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00220753 - Air Cleaners for Children and Adolescents With Asthma and Dog Allergy N/A
Completed NCT00232518 - Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis N/A
Completed NCT04126096 - Negative Predictive Value and NIC of Beta-Lactam Antibiotics. N/A
Completed NCT04046731 - Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation N/A
Completed NCT04004351 - Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
Not yet recruiting NCT05997784 - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Completed NCT04418999 - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus Early Phase 1
Completed NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02127801 - Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants Phase 1
Enrolling by invitation NCT05011071 - The Alberta BLOOM Premature Child Study
Not yet recruiting NCT06330974 - Allergy, Asthma, and Atopic Eczema in Finland
Terminated NCT02601690 - Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
Completed NCT02306473 - The Leaky Lung Test Early Phase 1
Completed NCT02596321 - A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma Phase 3